کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5813931 | 1556623 | 2015 | 6 صفحه PDF | دانلود رایگان |
- Tasimelteon was shown to have full agonist activity at both MT1 and MT2 receptors.
- Tasimelteon has greater affinity for the MT2 receptor than for the MT1 receptor.
- Tasimelteon has no affinity for other pharmacologically relevant receptors.
Hetlioz® (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). Tasimelteon was also shown to have no appreciable affinity for more than 160 other pharmacologically relevant receptors and several enzymes.
Journal: Neuropharmacology - Volume 91, April 2015, Pages 142-147